S0819
|
SWOG
|
A Randomized; Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S0931
|
SWOG
|
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy; A Phase III Study
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1007
|
SWOG
|
A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1011
|
SWOG
|
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1203
|
SWOG
|
A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S1207
|
SWOG
|
Phase III Randomized; Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1216
|
SWOG
|
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1300
|
SWOG
|
A Randomized; Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systematically After Previous Clinical Benefit From Crizotinib Monotherapy<br>
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
S1314
|
SWOG
|
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized; Muscle-Invasive Bladder Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1318
|
SWOG
|
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone; Vincristine; Methotrexate; 6-Mercaptopurine) for Patients >= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517); Prednisone and Blinatumomab for Patients >= 65 Years Of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL; and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|